Systematic review and network meta-analysis finds differences in efficacy and acceptability for adjunctive antipsychotics in MDD, suggesting personalized treatment options.
A systematic review and network meta‐analysis has found considerable differences in efficacy and acceptability among atypical antipsychotics used as adjunctive treatment for major depressive disorder (MDD). Lumateperone had the greatest effect size for efficacy, and aripiprazole had the highest level of acceptability. Results of the systematic review and meta‐analysis were published online May 6, 2026 in JAMA Psychiatry .
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: